Findings support the hypothesis that higher levels of amyloid in the brain is an indicator of the early stages of Alzheimer's disease.
The FXR1 protein in the brains of healthy, young rats functions in an amyloid form. The protein has previously been linked to controlling long-term memory formation and emotion.
Mathematical model describes the chemical reactions responsible for the formation of Alzheimer's-linked protein.
Researchers have identified the exact point at which healthy proteins become toxic in Alzheimer's disease. The findings could help to detect Alzheimer's before the disease progresses and develop treatments to stabilize tau proteins.
EGCG and tannic acid, polyphenols found in green tea and red wine, may help to effectively block the formation of toxic amyloid structures, researchers report. The findings may pave the way to developing new treatments for amyloid-related neurodegenerative disorders and genetic metabolic disorders.
A new study sheds light on the stabilizing forces of amyloid fibrils associated with Alzheimer's, type 2 diabetes and other neurodegenerative disorders.
Cortice Biosciences announced today results from placebo-controlled, double-blinded Phase 1 studies evaluating TPI 287, a brain penetrable microtubule stabilizing agent, for the treatment of Alzheimer’s disease, progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).
A new Johns Hopkins University study adds further evidence to the link between serotonin and dementia. According to researchers, lower serotonin levels may play a key role in memory decline and drive the progression of Alzheimer's.
A new technique allows researchers to analyze the structure a protein forms as it interacts with other proteins in a cell.
The findings reported in a new study could help improve the diagnosis and develop new treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's.
A new probe which allows researchers to quantify folded and misfolded protein levels in a cell could help pave the way for drug treatments for misfolding diseases such as Alzheimer's disease.
Researchers combined genetic data with neuroimaging in order to identify genes associated with amyloid plaque deposits in Alzheimer's disease patients. The study is believed to be the first genome-wide association study of plaque deposits using a specialized PET scan tracer that binds to amyloid.
